Aspire Biopharma Holdings, Inc.
ASBPHealthcare|Medical - Pharmaceuticals|US
$8.09
+1.33 (+19.67%)
Tangible Book / Share
$11.33
Cash / Share
$11.72
Financials
Financial Snapshot
Market Cap
$933.4K
Enterprise Value
-$11.2M
Revenue (TTM)
$97.7K
Net Income (TTM)
-$11.0M
Cash & Investments
$12.2M
Net Cash
$12.2M
Free Cash Flow (TTM)
-$7.2M
Operating CF (TTM)
-$7.2M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$12.2M
Quarterly Burn
$1.8M
Monthly Burn
$598.8K
Est. Runway
~6.8 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $0.00 | $497.3K | $0.00 | $3.6K | $1.0M | $12.2M | |
| Operating Cash Flow | -$260.00 | -$142.9K | -$653.1K | -$265.2K | -$4.9M | -$7.2M | |
| Free Cash Flow | -$260.00 | -$5.0M | -$653.1K | -$265.2K | -$4.9M | -$7.2M | |
| Capital Expenditure | $0.00 | -$4.9M | -$3.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $260.29 | $4.9M | -$284.8M | $257.6K | $5.9M | $19.1M |
R&D Spending
R&D (TTM)
$838.1K
R&D Intensity
858.2%
R&D Growth vs Prior
-9.3%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $6.2K | $97.7K | |
| R&D Expense | $0.00 | $0.00 | $72.0K | $144.4K | $923.9K | $838.1K | |
| R&D % of Revenue | — | — | — | — | 14897.0% | 858.2% | |
| SG&A | $27.8K | $976.3K | $1.3M | $1.1M | $18.4M | $6.2M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $6.2K | $97.7K | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $6.3K | $79.7K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$116.00 | $17.9K | |
| R&D | $0.00 | $0.00 | $72.0K | $144.4K | $923.9K | $838.1K | |
| SG&A | $27.8K | $976.3K | $1.3M | $1.1M | $18.4M | $6.2M | |
| Operating Income | -$25.5K | -$976.3K | -$1.3M | -$1.2M | -$19.4M | -$7.1M | |
| Interest Expense | $0.00 | $0.00 | $9.0K | $98.0K | $8.5M | $9.3M | |
| Pretax Income | -$25.5K | $3.3M | $4.5M | -$1.3M | -$24.5M | -$11.0M | |
| Net Income | -$25.5K | $3.3M | $4.5M | -$1.3M | -$24.5M | -$11.0M | |
| EPS (Diluted) | -0.04 | 3.72 | 9.31 | -34.17 | -16.38 | -8.02 | |
| EBITDA | $2.3K | -$976.3K | $5.8M | -$1.2M | -$11.3M | $3.3M | |
| Shares Out. (M) | 0.68 | 0.90 | 0.48 | 0.04 | 1.49 | 1.04 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $497.3K | $0.00 | $3.6K | $1.0M | $12.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $293.2K | $1.1M | $81.2K | $148.0K | $1.3M | $13.5M | |
| Total Assets | $293.2K | $300.2M | $20.0M | $148.0K | $1.3M | $13.5M | |
| Total Current Liabilities | $293.7K | $303.3K | $403.3K | $1.7M | $7.6M | $1.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $293.7K | $11.1M | $403.3K | $1.7M | $7.7M | $1.8M | |
| Stockholders' Equity | -$475.00 | $289.1M | $19.6M | -$1.5M | -$6.4M | $11.8M | |
| Retained Earnings | -$25.5K | -$9.9M | -$11.3M | -$2.8M | -$27.3M | -$31.7M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$260.00 | -$142.9K | -$653.1K | -$265.2K | -$4.9M | -$7.2M | |
| Capital Expenditure | $0.00 | -$4.9M | -$3.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$260.00 | -$5.0M | -$653.1K | -$265.2K | -$4.9M | -$7.2M | |
| Investing Cash Flow | $0.00 | -$4.9M | $284.9M | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $260.29 | $4.9M | -$284.8M | $257.6K | $5.9M | $19.1M | |
| Issuance of Stock | $0.00 | $1.0M | $155.8K | $343.4K | $265.8K | $8.7M | |
| Repurchase of Stock | $0.00 | $0.00 | -$284.9M | -$13.8M | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | -$252.9K | $0.00 | $1.7M | $6.6M | -$3.6M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $14.1M | $157.5K | |
| Net Change in Cash | $0.00 | -$185.5K | -$497.3K | -$7.5K | $1.0M | $12.0M |
Dilution Tracker
Shares outstanding grew 118.9% over 5 years — significant dilution
Shares Outstanding
0M
5-Year Share Growth
+118.9%
Stock Issuance (TTM)
$8.7M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.68 | 0.90 | 0.48 | 0.04 | 1.49 | 1.04 | |
| Change vs Prior % | — | 31.6% | -46.6% | -92.0% | 3799.3% | -30.6% | |
| Stock Issuance | $0.00 | $1.0M | $155.8K | $343.4K | $265.8K | $8.7M | |
| Stock Repurchase | $0.00 | $0.00 | -$284.9M | -$13.8M | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $14.1M | $157.5K |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | -1.9% | 18.3% | |
| Operating Margin % | — | — | — | — | -312016.9% | -7259.9% | |
| Net Margin % | — | — | — | — | -394725.1% | -11314.2% | |
| EBITDA Margin % | — | — | — | — | -182712.7% | 3367.4% | |
| FCF Margin % | — | — | — | — | -79385.5% | -7358.2% | |
| ROE % | 5363.2% | 1.2% | 22.8% | 85.1% | 383.9% | 1993.3% | |
| ROA % | -8.7% | 1.1% | 22.3% | -885.1% | -1865.7% | -81.6% | |
| ROIC % | -4.8% | -0.3% | -6.8% | -18.9% | 395.3% | -59.8% | |
| R&D / Revenue % | — | — | — | — | 14897.0% | 858.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -3731.8% | -37.2% | 9.6% | -1498.1% | |
| Net Income | 0.0% | 13211.8% | 33.6% | -129.3% | -1768.9% | |
| EPS (Diluted) | 0.0% | 10073.2% | 150.3% | -467.0% | 52.1% | |
| Operating Cash Flow | 0.0% | -54863.5% | -357.0% | 59.4% | -1756.6% | |
| Free Cash Flow | 0.0% | -1937596.5% | 87.0% | 59.4% | -1756.6% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 100.4% | 540.0% | |
| SG&A Expense | 0.0% | 3413.2% | 37.2% | -20.4% | 1627.8% | |
| Total Assets | 0.0% | 102274.0% | -93.3% | -99.3% | 786.7% | |
| Book Value / Share | 0.0% | 46250681.0% | -87.3% | -198.4% | 89.4% | |
| Debt | 0.0% | -88.3% | -55.7% | 10129.6% | 9.3% | |
| Diluted Shares | 0.0% | 31.6% | -46.6% | -92.0% | 3799.3% |
Valuation
P/E (TTM)At Loss
P/S9.56
P/B0.71
EV/EBITDAAt Loss
EV/Revenue-115.03
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$11.33
Net Current Assets / Share
$101.26
Graham Net-Net
$10.14
Cash / Share
$11.72
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -321394.10 | 3322.58 | 1403.65 | -403.86 | -9.67 | -1.01 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 38181.40 | 9.56 | |
| P/B Ratio | -17232737.38 | 38.42 | 320.03 | -343.54 | -37.14 | 0.71 | |
| EV/EBITDA | 3534451.15 | -11373.25 | 1077.87 | -437.98 | -20.93 | -3.42 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 38242.81 | -115.03 |
Analyst Estimates & Quality
Altman Z-Score
-3.46
Distress
Piotroski F-Score
5
Moderate